Skip to main content

Advanced Hodgkin lymphoma, insights from the GHSG HD21 trial

Intervista a Peter Borchmann By Giugno 14, 2024No Comments
Dai congressiIntervisteSpeciali

Peter Borchmann (University of Cologne) describes the HD21 trial outcomes: the novel BrECADD chemotherapy regimen significantly improves progression-free survival for patients with advanced-stage classical Hodgkin lymphoma, compared to the traditional BEACOPP regimen.